Nutrigenomics
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
MYCL Promotes Ipsc-Like Colony Formation Via MYC Box 0 and 2 Domains
MYCL promotes iPSC-like colony formation via MYC Box 0 and 2 domains Chiaki Akifuji Department of Life Science Frontiers, Center for iPS cell Research and Application (CiRA), Kyoto University Mio Iwasaki Department of Life Science Frontiers, Center for iPS cell Research and Application (CiRA), Kyoto University Yuka Kawahara Department of Life Science Frontiers, Center for iPS cell Research and Application (CiRA), Kyoto University Chiho Sakurai Department of Life Science Frontiers, Center for iPS cell Research and Application (CiRA), Kyoto University Yusheng Cheng Department of Life Science Frontiers, Center for iPS cell Research and Application (CiRA), Kyoto University Takahiko Imai Department of Life Science Frontiers, Center for iPS cell Research and Application (CiRA), Kyoto University Masato Nakagawa ( [email protected] ) Department of Life Science Frontiers, Center for iPS cell Research and Application (CiRA), Kyoto University Research Article Keywords: mycl, reprogramming, ipsc, eciency, induced Posted Date: August 19th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-817686/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License 1 MYCL promotes iPSC-like colony formation via MYC Box 0 and 2 domains 2 3 Authors 4 Chiaki Akifuji1, Mio Iwasaki1, Yuka Kawahara1, Chiho Sakurai1, Yusheng Cheng1, Takahiko 5 Imai1, and Masato Nakagawa1* 6 7 Affiliation 8 1 Department of Life Science Frontiers, Center for iPS cell Research and Application (CiRA), 9 Kyoto University, Kyoto 606-8507, Japan 10 11 *Correspondence: [email protected] 12 13 Abstract 14 Induced pluripotent stem cells (iPSCs) have the potential to differentiate into any cell in 15 the body and thus have attractive regenerative medicine potential. -
An Amino-Terminal Domain of Mxil Mediates Anti-Myc Oncogenic Activity and Interacts with a Homolog of the Yeast Transcriptional Repressor SIN3
CORE Metadata, citation and similar papers at core.ac.uk Provided by Elsevier - Publisher Connector Cell, Vol, 80, 777-786, March 10, 1995, Copyright © 1995 by Cell Press An Amino-Terminal Domain of Mxil Mediates Anti-Myc Oncogenic Activity and Interacts with a Homolog of the Yeast Transcriptional Repressor SIN3 Nicole Schreiber-Agus,*t Lynda Chin,*tt Ken Chen,t et al., 1990), and a carboxy-terminal a-helical domain re- Richard Torres, t Govinda Rao,§ Peter Guida,t quired for dimerization with another basic region-helix- Arthur h Skoultchi,§ and Ronald A. DePinhot Ioop-helix-leucine zipper (bHLH-LZ) protein, Max (Black- "rDepartments of Microbiology and Immunology wood and Eisenman, 1991; Prendergast et al., 1991). and of Medicine Many of the biochemical and biological activities of Myc §Department of Cell Biology appear to be highly dependent upon its association with ~Division of Dermatology Max (Blackwood and Eisenman, 1991 ; Prendergast et al., Albert Einstein College of Medicine 1991; Kretzner et al., 1992; Amati et al., 1993a, 1993b). Bronx, New York 10461 In addition to its key role as an obligate partner in transacti- vation-competent Myc-Max complexes, Max may also re- press Myc-responsive genes through the formation of Summary transactivation-inert complexes that are capable of bind- ing the Myc-Max recognition sequence (Blackwood et al., Documented interactions among members of the Myc 1992; Kato et al., 1992; Kretzner et al., 1992; Makela et superfamily support a yin-yang model for the regula- al., 1992; Mukherjee et al., 1992; Prendergast et al., 1992; tion of Myc-responsive genes in which t ransactivation- Ayer et al., 1993; Zervos et al., 1993). -
Original Article MYCN-Mediated Regulation of the HES1 Promoter Enhances the Chemoresistance of Small-Cell Lung Cancer by Modulating Apoptosis
Am J Cancer Res 2019;9(9):1938-1956 www.ajcr.us /ISSN:2156-6976/ajcr0100301 Original Article MYCN-mediated regulation of the HES1 promoter enhances the chemoresistance of small-cell lung cancer by modulating apoptosis Qin Tong1,2*, Shuming Ouyang3*, Rui Chen1, Jie Huang4, Linlang Guo1 1Department of Pathology, Zhujiang Hospital, Southern Medical University, 253 Gongye Road, Guangzhou 510282, People’s Republic of China; Departments of 2Radiation Oncology, 3Reproductive Medicine, The First Affiliated Hospital of University of South China, Hengyang 421001, People’s Republic of China; 4Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People’s Hospital & Guangdong Academy of Medical Sciences, Guangzhou 510080, People’s Republic of China. *Equal contributors. Received June 29, 2019; Accepted August 10, 2019; Epub September 1, 2019; Published September 15, 2019 Abstract: MYCN, a member of the MYC family, is correlated with tumorigenesis, metastasis and therapy in many malig nancies; however, its role in small-cell lung cancer (SCLC) remains unclear. In this study, we sought to identify the function of MYCN in SCLC chemoresistance and found that MYCN is overexpressed in chemoresistant SCLC cells. We used MYCN gain- and loss-of- function experiments to demonstrate that MYCN promotes in vitro and in vivo chemoresistance in SCLC by inhibiting apoptosis. Mechanistic investigations showed that MYCN binds to the HES1 promoter and exhibits transcriptional activity. Furthermore, MYCN mediated SCLC chemoresistance through HES1. Accordingly, the NOTCH inhibitor FLI-60 derepressed HES1 and diminished MYCN-induced chemoresistance in SCLC. Finally, the positive correlation between HES1 and MYCN was confirmed in SCLC patients. -
Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase -
1714 Gene Comprehensive Cancer Panel Enriched for Clinically Actionable Genes with Additional Biologically Relevant Genes 400-500X Average Coverage on Tumor
xO GENE PANEL 1714 gene comprehensive cancer panel enriched for clinically actionable genes with additional biologically relevant genes 400-500x average coverage on tumor Genes A-C Genes D-F Genes G-I Genes J-L AATK ATAD2B BTG1 CDH7 CREM DACH1 EPHA1 FES G6PC3 HGF IL18RAP JADE1 LMO1 ABCA1 ATF1 BTG2 CDK1 CRHR1 DACH2 EPHA2 FEV G6PD HIF1A IL1R1 JAK1 LMO2 ABCB1 ATM BTG3 CDK10 CRK DAXX EPHA3 FGF1 GAB1 HIF1AN IL1R2 JAK2 LMO7 ABCB11 ATR BTK CDK11A CRKL DBH EPHA4 FGF10 GAB2 HIST1H1E IL1RAP JAK3 LMTK2 ABCB4 ATRX BTRC CDK11B CRLF2 DCC EPHA5 FGF11 GABPA HIST1H3B IL20RA JARID2 LMTK3 ABCC1 AURKA BUB1 CDK12 CRTC1 DCUN1D1 EPHA6 FGF12 GALNT12 HIST1H4E IL20RB JAZF1 LPHN2 ABCC2 AURKB BUB1B CDK13 CRTC2 DCUN1D2 EPHA7 FGF13 GATA1 HLA-A IL21R JMJD1C LPHN3 ABCG1 AURKC BUB3 CDK14 CRTC3 DDB2 EPHA8 FGF14 GATA2 HLA-B IL22RA1 JMJD4 LPP ABCG2 AXIN1 C11orf30 CDK15 CSF1 DDIT3 EPHB1 FGF16 GATA3 HLF IL22RA2 JMJD6 LRP1B ABI1 AXIN2 CACNA1C CDK16 CSF1R DDR1 EPHB2 FGF17 GATA5 HLTF IL23R JMJD7 LRP5 ABL1 AXL CACNA1S CDK17 CSF2RA DDR2 EPHB3 FGF18 GATA6 HMGA1 IL2RA JMJD8 LRP6 ABL2 B2M CACNB2 CDK18 CSF2RB DDX3X EPHB4 FGF19 GDNF HMGA2 IL2RB JUN LRRK2 ACE BABAM1 CADM2 CDK19 CSF3R DDX5 EPHB6 FGF2 GFI1 HMGCR IL2RG JUNB LSM1 ACSL6 BACH1 CALR CDK2 CSK DDX6 EPOR FGF20 GFI1B HNF1A IL3 JUND LTK ACTA2 BACH2 CAMTA1 CDK20 CSNK1D DEK ERBB2 FGF21 GFRA4 HNF1B IL3RA JUP LYL1 ACTC1 BAG4 CAPRIN2 CDK3 CSNK1E DHFR ERBB3 FGF22 GGCX HNRNPA3 IL4R KAT2A LYN ACVR1 BAI3 CARD10 CDK4 CTCF DHH ERBB4 FGF23 GHR HOXA10 IL5RA KAT2B LZTR1 ACVR1B BAP1 CARD11 CDK5 CTCFL DIAPH1 ERCC1 FGF3 GID4 HOXA11 IL6R KAT5 ACVR2A -
(12) Patent Application Publication (10) Pub. No.: US 2003/0082511 A1 Brown Et Al
US 20030082511A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0082511 A1 Brown et al. (43) Pub. Date: May 1, 2003 (54) IDENTIFICATION OF MODULATORY Publication Classification MOLECULES USING INDUCIBLE PROMOTERS (51) Int. Cl." ............................... C12O 1/00; C12O 1/68 (52) U.S. Cl. ..................................................... 435/4; 435/6 (76) Inventors: Steven J. Brown, San Diego, CA (US); Damien J. Dunnington, San Diego, CA (US); Imran Clark, San Diego, CA (57) ABSTRACT (US) Correspondence Address: Methods for identifying an ion channel modulator, a target David B. Waller & Associates membrane receptor modulator molecule, and other modula 5677 Oberlin Drive tory molecules are disclosed, as well as cells and vectors for Suit 214 use in those methods. A polynucleotide encoding target is San Diego, CA 92121 (US) provided in a cell under control of an inducible promoter, and candidate modulatory molecules are contacted with the (21) Appl. No.: 09/965,201 cell after induction of the promoter to ascertain whether a change in a measurable physiological parameter occurs as a (22) Filed: Sep. 25, 2001 result of the candidate modulatory molecule. Patent Application Publication May 1, 2003 Sheet 1 of 8 US 2003/0082511 A1 KCNC1 cDNA F.G. 1 Patent Application Publication May 1, 2003 Sheet 2 of 8 US 2003/0082511 A1 49 - -9 G C EH H EH N t R M h so as se W M M MP N FIG.2 Patent Application Publication May 1, 2003 Sheet 3 of 8 US 2003/0082511 A1 FG. 3 Patent Application Publication May 1, 2003 Sheet 4 of 8 US 2003/0082511 A1 KCNC1 ITREXCHO KC 150 mM KC 2000000 so 100 mM induced Uninduced Steady state O 100 200 300 400 500 600 700 Time (seconds) FIG. -
Targeting MYC-Induced Metabolic Reprogramming and Oncogenic Stress in Cancer
Author Manuscript Published OnlineFirst on July 29, 2013; DOI: 10.1158/1078-0432.CCR-12-3629 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Molecular Pathways: Targeting MYC-induced Metabolic Reprogramming and Oncogenic Stress in Cancer Bo Li and M. Celeste Simon Authors’ affiliation: Abramson Family Cancer Research Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Howard Hughes Medical Institute, Philadelphia, Pennsylvania Corresponding author: M. Celeste Simon, 456 BRB II/III, Abramson Family Cancer Research Institute, Perelman School of Medicine at the University of Pennsylvania, 421 Curie Blvd., Philadelphia, PA 19104. Phone: 215-746-5532; Fax: 215-746-5511; Email: [email protected] Grant support: The authors’ laboratory is supported by the Howard Hughes Medical Institute and by NIH Grant CA104838 (to M.C. Simon). M.C. Simon is an Investigator of the Howard Hughes Medical Institute. The authors have no conflicts of interest. Abstract MYC is a multi-functional transcription factor that is deregulated in many human cancers. MYC impacts a collaborative genetic program that orchestrates cell proliferation, metabolism, and stress responses. Although the progression of MYC-amplified tumors shows robust dependence on MYC activity, directly targeting MYC as a therapeutic method has proven to be technically difficult. Therefore, alternative approaches are currently under development with a focus on interference with MYC-mediated downstream effects. To fuel rapid cell growth, MYC reprograms cancer cell metabolism in a way that is substantially different from normal cells. The MYC-induced metabolic signature is characterized by enhanced glucose and glutamine uptake, increased lactate production, and altered amino acid metabolism. -
Whole Exome Sequencing in Families at High Risk for Hodgkin Lymphoma: Identification of a Predisposing Mutation in the KDR Gene
Hodgkin Lymphoma SUPPLEMENTARY APPENDIX Whole exome sequencing in families at high risk for Hodgkin lymphoma: identification of a predisposing mutation in the KDR gene Melissa Rotunno, 1 Mary L. McMaster, 1 Joseph Boland, 2 Sara Bass, 2 Xijun Zhang, 2 Laurie Burdett, 2 Belynda Hicks, 2 Sarangan Ravichandran, 3 Brian T. Luke, 3 Meredith Yeager, 2 Laura Fontaine, 4 Paula L. Hyland, 1 Alisa M. Goldstein, 1 NCI DCEG Cancer Sequencing Working Group, NCI DCEG Cancer Genomics Research Laboratory, Stephen J. Chanock, 5 Neil E. Caporaso, 1 Margaret A. Tucker, 6 and Lynn R. Goldin 1 1Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 2Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 3Ad - vanced Biomedical Computing Center, Leidos Biomedical Research Inc.; Frederick National Laboratory for Cancer Research, Frederick, MD; 4Westat, Inc., Rockville MD; 5Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; and 6Human Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA ©2016 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2015.135475 Received: August 19, 2015. Accepted: January 7, 2016. Pre-published: June 13, 2016. Correspondence: [email protected] Supplemental Author Information: NCI DCEG Cancer Sequencing Working Group: Mark H. Greene, Allan Hildesheim, Nan Hu, Maria Theresa Landi, Jennifer Loud, Phuong Mai, Lisa Mirabello, Lindsay Morton, Dilys Parry, Anand Pathak, Douglas R. Stewart, Philip R. Taylor, Geoffrey S. Tobias, Xiaohong R. Yang, Guoqin Yu NCI DCEG Cancer Genomics Research Laboratory: Salma Chowdhury, Michael Cullen, Casey Dagnall, Herbert Higson, Amy A. -
Transcriptome Analysis of the Uterus of Hens Laying Eggs Differing in Cuticle Deposition Sandra Poyatos Pertiñez1* , Peter W
Poyatos Pertiñez et al. BMC Genomics (2020) 21:516 https://doi.org/10.1186/s12864-020-06882-7 RESEARCH ARTICLE Open Access Transcriptome analysis of the uterus of hens laying eggs differing in cuticle deposition Sandra Poyatos Pertiñez1* , Peter W. Wilson1, Wiebke Icken2, David Cavero3, Maureen M. Bain4, Anita C. Jones5 and Ian C. Dunn1 Abstract Background: Avian eggs have a proteinaceous cuticle. The quantity of cuticle varies and the deposition of a good cuticle in the uterus (Shell-gland) prevents transmission of bacteria to the egg contents. Results: To understand cuticle deposition, uterus transcriptomes were compared between hens with i) naturally good and poor cuticle and, ii) where manipulation of the hypothalamo-pituitary-gonadal-oviduct axis produced eggs with or without cuticle. The highest expressed genes encoded eggshell matrix and cuticle proteins, e.g. MEPE (OC-116), BPIFB3 (OVX-36), RARRES1 (OVX-32), WAP (OVX-25), and genes for mitochondrial oxidative phosphorylation, active transport and energy metabolism. Expression of a number of these genes differed between hens laying eggs with or without cuticle. There was also a high expression of clock genes. PER2, CRY2, CRY1, CLOCK and BMAL1 were differentially expressed when cuticle deposition was prevented, and they also changed throughout the egg formation cycle. This suggests an endogenous clock in the uterus may be a component of cuticle deposition control. Cuticle proteins are glycosylated and glycosaminoglycan binding genes had a lower expression when cuticle proteins were deposited on the egg. The immediate early genes, JUN and FOS, were expressed less when the cuticle had not been deposited and changed over the egg formation cycle, suggesting they are important in oviposition and cuticle deposition. -
Lineage Transcription Factors Co-Regulate Subtype-Specific Genes Providing a Roadmap For
bioRxiv preprint doi: https://doi.org/10.1101/2020.08.13.249029; this version posted August 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Lineage transcription factors co-regulate subtype-specific genes providing a roadmap for systematic identification of small cell lung cancer vulnerabilities Karine Pozo1,2, Rahul K. Kollipara3, Demetra P. Kelenis1, Kathia E. Rodarte1, Xiaoyang Zhang4, John D. Minna5,6,7,8 and Jane E. Johnson1,6,8 1Department of Neuroscience, 2Department of Surgery, 3McDermott Center for Human Growth and Development, UT Southwestern Medical Center, Dallas, TX 75390, USA 4Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 5Hamon Center for Therapeutic Oncology Research, 6Simmons Comprehensive Cancer Center, 7Department of Internal Medicine, 8Department of Pharmacology, UT Southwestern Medical Center, Dallas, TX 75390, USA JDM receives licensing fees for lung cancer lines from the NIH and UT Southwestern. 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.08.13.249029; this version posted August 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. ABSTRACT Lineage-defining transcription factors (LTFs) play key roles in tumor cell growth, making them highly attractive, but currently “undruggable”, small cell lung cancer (SCLC) vulnerabilities. -
Toxicogenomic Approach to Impact Assessment of Whole Wastewater Effluents and Development of Effluent- Title Responsive Biomarker
Toxicogenomic Approach to Impact Assessment of Whole Wastewater Effluents and Development of Effluent- Title Responsive Biomarker Author(s) 山村, 宏江 Citation 北海道大学. 博士(工学) 甲第11137号 Issue Date 2013-09-25 DOI 10.14943/doctoral.k11137 Doc URL http://hdl.handle.net/2115/77180 Type theses (doctoral) File Information Hiroe_Yamamura.pdf Instructions for use Hokkaido University Collection of Scholarly and Academic Papers : HUSCAP Doctoral Thesis Toxicogenomic Approach to Impact Assessment of Whole Wastewater Effluents and Development of Effluent-Responsive Biomarker Hiroe Hara-Yamamura Acknowledgement My doctoral research works presented here cannot be completed without a numerous number of tangible and intangible supports from my peers, my supervisor, instructors, friends, and family. I would first express my deepest gratitude to Prof. Satoshi OKABE for his technical advices and crisp ideas which often came to break the deadlock of my research progress, and for continued provision of another chance to me, even in the least fruitful season. Indeed, my three years in Prof. OKABE’s lab was “luxuri- ous” time in my life with a lot of supports, encouragements, and chances. In addition, I appreciate both Prof. Daisuke SANO and Dr. Satoshi ISHII for offering their insights on my experimental design and data analysis as well as giving me words of encouragements from time to time. Also, thank you to Prof. Takashi KUSUI from Toyama Prefectural University for his assistance to bioassay techniques and valuable discussion dur- ing my 1st year and 2nd year evaluation presentations. Furthermore, I would like to express my gratitude to specific efforts kindly provide by: Mr. Kenzo Kudo, Prof. -
Constitutive Expression of Ectopic C-Myc Delays Glucocorticoid-Evoked Apoptosis of Human Leukemic CEM-C7 Cells
Oncogene (2001) 20, 4629 ± 4639 ã 2001 Nature Publishing Group All rights reserved 0950 ± 9232/01 $15.00 www.nature.com/onc Constitutive expression of ectopic c-Myc delays glucocorticoid-evoked apoptosis of human leukemic CEM-C7 cells Rheem D Medh*,1, Aixia Wang1, Feng Zhou2 and E Brad Thompson*,1 1Department of Human Biological Chemistry and Genetics, The University of Texas Medical Branch, Galveston, Texas, TX-77555-0645, USA Sensitivity to glucocorticoid (GC)-evoked apoptosis in roles in normal thymocyte selection and in the therapy lymphoid cell lines correlates closely with GC-mediated of lymphoid malignancies (Gaynon and Carrel, 1999; suppression of c-Myc expression. To establish a Leung and Munck, 1975). GC-evoked lympholytic functional role for c-Myc in GC-mediated apoptosis, responses are mediated via the GC receptor (GR), we have stably expressed MycERTM, the human c-Myc and can be blocked by the GR antagoinst RU 38486 protein fused to the modi®ed ligand-binding domain of (Homo-Delarche, 1984; Thompson et al., 1995). the murine estrogen receptor a, in GC-sensitive CEM- Ligand-activated GR is known to function as a C7-14 cells. In CEM-C7-14 cells, MycERTM constitu- transcription factor for numerous genes; hence the tively imparts c-Myc functions. Cells expressing My- current hypothesis for GC-evoked apoptosis favors cERTM (C7-MycERTM) exhibited a marked reduction in receptor mediated alteration in expression of key cell death after 72 h in 100 nM dexamethasone (Dex), vitality and/or death genes (Medh and Thompson, with 10 ± 20-fold more viable cells when compared to the 2000; Montague and Cidlowski, 1995; Thompson, parental CEM-C7-14 clone.